Sr. Director/Vice President Clinical Operations

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris

First IND clearance of a product candidate derived from the CABA™ platform PHILADELPHIA, Oct. 01, 2019 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Company), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for the treatment of patients with B cell-mediated autoimmune diseases, today announced that it has received clearance […]

Cabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel

Mr. Stalter joins Cabaletta with more than 20 years of general corporate and deal-making experience in small biotech and large pharma organizations PHILADELPHIA, September 5, 2019 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, today announced the appointment […]

Vice President, Business Development

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Director/Senior Director of R&D Operations

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Director of GMP Quality

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Laboratory Manager

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Director/Sr. Director of Gene Transfer Technologies

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]